r earlier terminated by PDL. Old Notes must be tendered on or prior to the expiration of the offer, and tendered Old Notes may be withdrawn at any time on or prior to the expiration of the offer. Validly withdrawn Old Notes will be returned to the holder in accordance with the terms of the offer. Following the expiration of the offer and subject to the terms of the offer, PDL will accept all Old Notes validly tendered and not validly withdrawn prior to the expiration of the offer and will issue the New Notes and pay the exchange fee promptly thereafter.
The information agent for the exchange offer is Georgeson, Inc. Holders of Old notes who have questions or would like additional copies of the exchange offer documents may call the information agent, Georgeson Inc., at (866) 541-3547. Banks and brokers should call Georgeson at (212) 440-9800.
This description of the exchange offer is only a summary and is qualified in its entirety by all of the terms and conditions of the exchange offer set forth in the Offering Memorandum, Letter of Transmittal and other materials relating to the exchange offer, all as filed with the Securities and Exchange Commission. Neither PDL's Board of Directors nor any other person makes any recommendation as to whether holders of Old Notes should choose to tender and exchange their Old Notes for New Notes, and no one has been authorized to make such a recommendation. The Company's has been advised by JMP Securities LLC in connection with this exchange offer.
The issuance of the New Notes will not be registered under the Securities Act of 1933, as amended, in reliance on an exemption from registration thereunder.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws oPage: 1 2 3 4 Related medicine technology :1
. Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting2
. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference3
. PDL BioPharma Announces Third Quarter 2011 Financial Results4
. Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.5
. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results6
. PDL BioPharma to Announce Third Quarter 2011 Financial Results on November 9, 20117
. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results8
. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value9
. Sentry BioPharma Services Earns a GSA Federal Supply Schedule Contract #GS-10F-0432X10
. Genesis Biopharma Signs Worldwide License Agreement with the NIH for Adoptive Cell Therapy to Treat a Variety of Cancers11
. Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer